

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Shanghai Bio-heart Biological Technology Co., Ltd.**  
**上海百心安生物技術股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2185)**

**DATE OF BOARD MEETING**

The board of directors (the “**Board**”) of Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”) hereby announces that a meeting of the Board will be held on Thursday, March 26, 2026 for the purpose of, inter alia, considering and approving the annual results of the Company and its subsidiaries for the year ended December 31, 2025 and its publication, and considering the recommendation for payment of a final dividend, if any.

By Order of the Board

**Shanghai Bio-heart Biological Technology Co., Ltd.**

**Philip Li WANG**

*Chairman and executive director*

Shanghai, the People's Republic of China, March 16, 2026

*As at the date of this announcement, the Board comprises Mr. Philip Li WANG as Chairman and executive director, Mr. Yunqing WANG and Ms. Peili WANG as executive directors, and Mr. Yiqing CHEN, Mr. Xubo LU and Mr. Yifei JIANG as independent non-executive directors.*